Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 352-357

  Castanheira, Mariana ^a   Duncanson, Frederick P ^b   Diekema, Daniel J ^c   Guarro, Josep ^d   Jones, Ronald N ^a,e   Pfaller, Michael A ^a,c  

^a JMI LABORATORIES   (United States)

^b EISAI INC   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; E 1210; ITRACONAZOLE; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTICLE; BROTH DILUTION; CLINICAL AND LABORATORY STANDARDS INSTITUTE; EUROPEAN COMMITTEE FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING; FUNGUS ISOLATION; FUSARIUM; FUSARIUM OXYSPORUM; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR THERAPY; NONHUMAN; PRIORITY JOURNAL; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM AURANTIACUM; SCEDOSPORIUM PROLIFICANS;

ACYLATION; AMINOPYRIDINES; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ECHINOCANDINS; FUSARIUM; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; INOSITOL; ISOXAZOLES; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SCEDOSPORIUM; TRIAZOLES;

EID: 84455173118     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05414-11     Document Type: Article

References (40)

1. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. 2008. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J. Antimicrob. Chemother. 61:805-809. (Pubitemid 351426063)
2. Azor M, Gene J, Cano J, Guarro J. 2007. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob. Agents Chemother. 51:1500-1503. (Pubitemid 46586837)
3. Balajee SA, et al. 2009. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J. Clin. Microbiol. 47:877-884.
4. Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. 2007. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand. J. Infect. Dis. 39:87-90. (Pubitemid 46277156)
5. Chang DC, et al. 2006. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 296:953-963. (Pubitemid 44285372)
6. Clinical Laboratory Standards Institute. 2008. M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Clinical Laboratory Standards Institute, Wayne, PA.
7. Cortez KJ, et al. 2008. Infections caused by Scedosporium spp. Clin. Microbiol. Rev. 21:157-197.
8. Cuenca-Estrella M, et al. 2007. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 13:1018-1022. (Pubitemid 47382259)
9. Doczi I, Gyetvai T, Kredics L, Nagy E. 2004. Involvement of Fusarium spp. in fungal keratitis. Clin. Microbiol. Infect. 10:773-776. (Pubitemid 39276309)
10. EUCAST. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. http://www.eucast.org/documents/technical-notes/. Accessed 16 November 2010.
11. Gilgado F, Cano J, Gene J, Guarro J. 2005. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J. Clin. Microbiol. 43:4930-4942. (Pubitemid 41483987)
12. Gosbell IB, et al. 2003. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 46:233-236. (Pubitemid 36808246)
13. Hata K, et al. 2011. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob. Agents Chemother. 55:4543-4551.
14. Howden BP, Slavin MA, Schwarer AP, Mijch AM. 2003. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. 22:111-113. (Pubitemid 36349974)
15. Reference deleted.
16. Leaw SN, et al. 2006. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J. Clin. Microbiol. 44:693-699.
17. Lu Q, et al. 2011. Identification of Pseudallescheria and Scedosporium species by three molecular methods. J. Clin. Microbiol. 49:960-967.
18. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. 2002. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. 34:1648-1650. (Pubitemid 34615452)
19. Miyazaki M, et al. 2011. In vitro antifungal activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob. Agents Chemother. 55:4652-4658.
20. Nesky MA, McDougal EC, Peacock JE Jr. 2000. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. 31:673-677. (Pubitemid 32295485)
21. Nucci M, Anaissie E. 2007. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 20:695-704. (Pubitemid 47623773)
22. Nucci M, Anaissie E. 2002. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. 35:909-920. (Pubitemid 35178307)
23. Nucci M, et al. 2004. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 38:1237-1242. (Pubitemid 38608564)
24. O'Donnell K, et al. 2007. Phylogenetic diversity and microsphere array-based genotyping of human pathogenic Fusaria, including isolates from the multistate contact lens-associated U.S. keratitis outbreaks of 2005 and 2006. J. Clin. Microbiol. 45:2235-2248. (Pubitemid 47203799)
25. O'Donnell K, et al. 2008. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J. Clin. Microbiol. 46:2477-2490.
26. Perfect JR, et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131. (Pubitemid 36549632)
27. Pfaller MA, et al. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
28. Pfaller MA, et al. 2009. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47:3323-3325.
29. Pfaller MA, et al. 2011. In vitro activity of a novel broad-spectrum antifungal, E1210,andtested against Aspergillus spp. determinedbyCLSIandEUCASTbroth microdilution methods. Antimicrob. Agents Chemother. 55:5155-5158.
30. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
31. Pfaller MA, Watanabe N, Castanheira M, Messer SA, Jones RN. 2011. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. J. Antimicrob. Chemother. 66:2581-2584.
32. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
33. Raad II, et al. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1398-1403.
34. Singh RP, McCluskey P. 2005. Scedosporium prolificans sclerokeratitis 10 years after pterygium excision with adjunctive mitomycin C. Clin. Exp. Ophthalmol. 33:433-434. (Pubitemid 44144619)
35. Sutton DA. 2008. Rare and emerging agents of hyalohyphomycosis. Curr. Fungal Infect. Reports 2:134-142.
36. Tsukahara K, et al. 2003. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol. Microbiol. 48:1029-1042. (Pubitemid 36628267)
37. Umemura M, et al. 2003. GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast. J. Biol. Chem. 278:23639-23647. (Pubitemid 36830186)
38. Wang H, et al. 2011. Accurate and practical identification of 20 Fusarium species by seven-locus sequence analysis and reverse line blot hybridization, and an in vitro antifungal susceptibility study. J. Clin. Microbiol. 49:1890-1898.
39. Watanabe N, Horii T, Miyazaki M, Hata K. 2010. E1210, a new broad-spectrum antifungal, inhibits glycosylphosphatidylinositol (GPI) biosynthesis and affects Candida albicans cell characteristics, abstr F1-841. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.
40. Whyte M, et al. 2005. Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr. Infect. Dis. J. 24:375-377. (Pubitemid 40525349)